About Pulse Biosciences, Inc - Common Stock (PLSE)
Pulse Biosciences is a biomedical technology company that focuses on developing innovative treatment options using its proprietary Nano-Pulse Stimulation (NPS) platform. This cutting-edge technology utilizes nanosecond-duration electrical pulses to selectively induce biological responses in cells, primarily aimed at treating various medical conditions such as dermatological issues and cancer. By harnessing the power of NPS, Pulse Biosciences seeks to provide safe and effective solutions that enhance patient outcomes while minimizing the side effects commonly associated with traditional therapies. The company is dedicated to advancing its clinical applications through ongoing research and development efforts. Read More
Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program.
On the company’s earnings call, Co-Chairman and C
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, NV.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on April 25, 2026, in Chicago, Illinois.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced the strengthening of its executive leadership team with the appointment of Liane Teplitsky as Chief Operating Officer and expanded role of Dr. David Kenigsberg as full-time Chief Medical Officer.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF).
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference.
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first patient enrollments in the multi-center first-in-human feasibility study of the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for treatment of T1N0M0 papillary thyroid microcarcinoma (PTM), a small, slow-growing, and most common form of thyroid cancer. The initial procedures were successfully completed at Sarasota Memorial Health Care System in Sarasota, Florida, and The University of Texas MD Anderson Cancer Center in Houston, Texas.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data on outcomes durability from the nPulse Vybrance Percutaneous Electrode System First-in-Human ablation study of benign thyroid nodules using nsPFA energy.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a podium presentation and a product theatre presentation at the Annual North American Society for Interventional Thyroidology 2026 meeting, being held March 6-7 in Portland, Oregon.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on February 18, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 46th Annual TD Cowen Healthcare Conference in Boston.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects. The data were presented today at the 31st Annual AF Symposium 2026 meeting, taking place February 5-7, 2026, in Boston, MA.
